Fig. 1. Effect of deltarasin on cell viability and KRAS signaling in KRAS-dependent lung cancer cells, KRAS-independent lung cancer cells with BRAF mutation and WT-KRAS normal lung fibroblast cells.

. (A) A549, H358, H1395, and CCD19-Lu cells were treated with deltarasin (0, 1.25, 2.5, 5, and 10 μM) for 72 h and the percentages of cell viability were measured by MTT assays. (B) Representative western blot data of the levels of p-CRAF, CRAF, p-AKT, AKT, p-ERK, ERK, and GAPDH of A549, H358, and CCD19-Lu cells after 24 h deltarasin treatment (0, 1.25, 2.5, and 5 μM). Data were expressed as mean ± SD of three independent experiments (each in triplicate). ***P < 0.001, **P < 0.01 when compared with control